SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Regeneron Pharmaceuticals, Inc. – ‘8-K’ for 5/2/24

On:  Thursday, 5/2/24, at 7:06am ET   ·   For:  5/2/24   ·   Accession #:  1804220-24-15   ·   File #:  0-19034

Previous ‘8-K’:  ‘8-K’ on / for 2/2/24   ·   Latest ‘8-K’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/02/24  Regeneron Pharmaceuticals, Inc.   8-K:2,9     5/02/24   12:517K                                   Gregorio Michele/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     25K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML    333K 
 6: R1          Cover                                               HTML     42K 
 7: R2          Cover                                               HTML     10K 
 9: XML         IDEA XML File -- Filing Summary                      XML     13K 
12: XML         XBRL Instance -- regn-20240502_htm                   XML     14K 
 8: EXCEL       IDEA Workbook of Financial Report Info              XLSX      9K 
 4: EX-101.LAB  XBRL Labels -- regn-20240502_lab                     XML     62K 
 5: EX-101.PRE  XBRL Presentations -- regn-20240502_pre              XML     34K 
 3: EX-101.SCH  XBRL Schema -- regn-20240502                         XSD     11K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    17K 
11: ZIP         XBRL Zipped Folder -- 0001804220-24-000015-xbrl      Zip     43K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:   C: 
  regn-20240502  
 i 0000872589 i false00008725892024-05-022024-05-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM  i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  i May 2, 2024 ( i May 2, 2024)

 i REGENERON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 i New York
 i 13-3444607
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
 i 777 Old Saw Mill River Road,  i Tarrytown,  i New York  i 10591-6707
(Address of Principal Executive Offices, including zip code)

( i 914)  i 847-7000
Registrant's telephone number, including area code


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 i  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 i  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 i  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 i  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
 i Common Stock - par value $.001 per share i REGN i NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  i 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐








Item 2.02    Results of Operations and Financial Condition.

On May 2, 2024, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended March 31, 2024. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.

The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.


Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release, dated May 2, 2024, Reporting First Quarter 2024 Financial and Operating Results.

104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REGENERON PHARMACEUTICALS, INC.
By:/s/ Joseph J. LaRosa
Name:Joseph J. LaRosa
Title:Executive Vice President, General Counsel and Secretary




Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:5/2/24None on these Dates
3/31/24
 List all Filings 
Top
Filing Submission 0001804220-24-000015   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 17, 6:56:51.1pm ET